Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. News
  5. Trial Results

Trial Results

Thumbnail
August 16, 2022

Viridian takes on Horizon

Early data in thyroid eye disease impress, but unanswered questions include the size of the market.

Thumbnail
August 15, 2022

Canakinumab’s cancer career ends with a whimper

Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.

Article image
Vantage logo
August 15, 2022

Is Pfizer’s pneumococcal dominance under threat?

Article image
Vantage logo
August 15, 2022

Finally! A positive surprise for Gilead

Article image
Vantage logo
August 09, 2022

Cincor’s blood pressure win quickens investors’ pulses

Article image
Vantage logo
August 09, 2022

Verona breathes easier

Article image
Vantage logo
August 09, 2022

Uniqure’s Huntington’s hopes take a hit

Article image
Vantage logo
August 08, 2022

Karuna bucks the neuro trend

The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.

Article image
Vantage logo
August 03, 2022

Alnylam’s heart beats stronger

A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.

Article image
Vantage logo
August 02, 2022

Eliem Therapeutics feels more pain

Article image
Vantage logo
August 02, 2022

Roche tries to jump ahead with subcutaneous Tecentriq

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.